Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis - Scorecard - MDSpire
Advertisement
Gastrointestinal toxicity associated with cyclin-dependent kinase 4/6 inhibitors in breast cancer patients: insights from a real-world pharmacovigilance analysis
Clinical Scorecard: Gastrointestinal Adverse Effects Linked to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Findings from a Real-World Pharmacovigilance Study
At a Glance
Category
Detail
Condition
Breast Cancer
Key Mechanisms
Inhibition of CDK4 and CDK6 kinases, blocking phosphorylation of retinoblastoma protein, arresting cell cycle at G1 phase.
Target Population
Patients with locally advanced or metastatic breast cancer, including those with hormone receptor-positive, HER2-negative subtypes.
Care Setting
Pharmacovigilance and safety monitoring in clinical practice.
Key Highlights
63,722 reports associated with CDK4/6 inhibitors, 18,589 involving GI adverse events.
Palbociclib had the largest proportion of GI AE reports; ribociclib had the highest serious AE rate.
Over 80% of positive GI pharmacovigilance signals were absent from current prescribing information.
Median onset time for GI AEs varied: 15 days for abemaciclib, 27 days for ribociclib, 49 days for palbociclib.
Serious GI AEs more frequent in older patients, low weight, ribociclib exposure, and concomitant therapy.
Guideline-Based Recommendations
Diagnosis
Monitor for gastrointestinal adverse events in patients receiving CDK4/6 inhibitors.
Management
Consider dose adjustments or treatment interruptions for patients experiencing significant GI AEs.
Monitoring & Follow-up
Utilize pharmacovigilance data to identify and assess GI safety profiles of CDK4/6 inhibitors.
Risks
Increased risk of serious GI AEs in older patients and those on concomitant therapies.
Patient & Prescribing Data
Breast cancer patients receiving CDK4/6 inhibitors.
Diarrhea is a key GI toxicity, particularly for abemaciclib.
Clinical Best Practices
Conduct systematic evaluations of GI safety profiles for CDK4/6 inhibitors.
Prioritize monitoring for GI AEs in vulnerable patient populations.
